DexCom (DXCM) Reports Q1 2026 Revenue of $1.19B with 15% Growth

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to invest in for the next 2 years. On April 30, DexCom reported Q1 ...

Dexcom to Host Investor Day on May 14, 2026

DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT). The event will include ...
Business Wire

Dexcom Helps People With Diabetes Take the First Step to Discover What They’re Made Of on World Diabetes Day

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...
Nasdaq

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Medical Device Network on MSN

Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook

Dexcom has opted not to raise its FY26 revenue outlook due to the current geopolitical environment.
Hosted on MSN

DexCom reports strong Q1 as OTC CGMs reach new users

DexCom posted better-than-expected Q1 2026 results, with revenue up 15% year-over-year on strong uptake of its G7 continuous glucose monitor and expanded coverage for type 2 diabetes patients not ...
Business Wire

Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Seeking Alpha

Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025.
Nasdaq

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...
Seeking Alpha

Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc (DXCM). (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...
The Motley Fool

3 Reasons to Buy DexCom Stock Like There's No Tomorrow

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...